China Pharma Holdings, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US16941T2033
USD
1.66
-0.14 (-7.78%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About China Pharma Holdings, Inc. stock-summary
stock-summary
China Pharma Holdings, Inc.
Pharmaceuticals & Biotechnology
China Pharma Holdings, Inc. is a holding company. The Company conducts its production, marketing, finance, development and administrative activities through its subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd. (Helpson) in the People's Republic of China (PRC). It is engaged in the development, manufacture and marketing of pharmaceutical products for human use in connection with various diseases and medical conditions in the PRC. It manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, oral solutions and granules. Its pharmaceutical products are sold on a prescription basis and are approved by the China Food and Drug Administration (the CFDA). The Company manufactured over 20 pharmaceutical products for various diseases and medical indications. It offers products for Central Nervous System (CNS) and Cerebral-Cardiovascular Diseases, Anti-infection and Respiratory Diseases, Digestive Diseases and Others.
Company Coordinates stock-summary
Company Details
2Nd Floor, No. 17, Jinpan Road, Haikou , HAIKOU HAN : 570216
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 1 Schemes (0.02%)

Foreign Institutions

Held by 3 Foreign Institutions (0.77%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Zhilin Li
Chairman of the Board, President, Chief Executive Officer, Interim Chief Financial Officer
Heung Tsui
Director
Gene Bennett
Independent Director
Baowen Dong
Independent Director
Yingwen Zhang
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
1 Million
(Quarterly Results - Jun 2025)
Net Profit:
-1 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 6 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.42

stock-summary
Return on Equity

-55.05%

stock-summary
Price to Book

0.87